Amalgamated Bank’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Amalgamated Bank’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,611	Closed	-$208K	–	3217
2023 Q1	$208K	Sell	8,611 -830	-9%	-$10.4K	﹤0.01%	1789
2022 Q4	$100K	Buy	9,441 +448	+5%	+$3.62K	﹤0.01%	2138
2022 Q3	$40K	Buy	8,993 +421	+5%	+$1.92K	﹤0.01%	2559
2022 Q2	$34K	Buy	8,572 +1,866	+28%	+$8.85K	﹤0.01%	2658
2022 Q1	$49K	Buy	+6,706	New	+$40.1K	﹤0.01%	2499

Other funds holding PRVB

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Amalgamated Bank's PRVB Position: Q2 2023 in Review

Amalgamated Bank sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 8,611 shares — an estimated $208K sold.

Amalgamated Bank first reported a position in PRVB in Q1 2022 and held it in 5 quarters. The position peaked at $208K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Amalgamated Bank reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Amalgamated Bank sold 8,611 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $208K.
Amalgamated Bank first reported a position in Provention Bio, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Amalgamated Bank's Provention Bio, Inc. Common Stock position peaked at $208K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Amalgamated Bank's 13F filing for Q2 2023, filed 11 Aug 2023.